A study has found that sirolimus-coated balloons vs thin drug-eluting stents in in-stent restenosis show similar favorable clinical outcomes.

PRNewswire New Delhi [India]1 Translumina was incorporated in 2011 as a sales marketing company specialising in coronary ...

The vascular stents market is anticipated to grow from USD 11.4 billion in 2024 to USD 15.6 billion by 2029, with a CAGR of 6.5%. This ...

The DynamX Bioadaptor device was noninferior to DES for TLF overall, but a landmark analysis reveals a potential strength.

Translumina, established in 2011, focuses on coronary intervention devices and has expanded its manufacturing capabilities and product lines. The company aims to highlight Indian innovation in the ...

Novel drug-coated balloons (DCB) did not outshine standard treatment with second generation drug-eluting stents (DES ... arteries (that supply blood to the heart). The conventional treatment ...

The trial was set up to give DCBs their “best shot” in this patient group, says one researcher, but it’s tough to beat current DES.

Undergoing percutaneous coronary intervention (PCI) for narrowed arteries with a novel bioadaptor is at least as effective as ...

Using optimal coherence tomography (OCT) to guide stent implantation during percutaneous coronary intervention (PCI) in ...

A triptych of Taylor Park is displayed at Frida's Bakery, while Largo Art has many of Gallagher's framed pieces in the style ...